期刊文献+

温肾健脾、祛毒活血法对早期糖尿病肾病及IL-6、TNF-α的影响 被引量:12

下载PDF
导出
摘要 目的观察温肾健脾、祛毒活血法对早期糖尿病肾病(DN)患者血糖、血脂、24h尿蛋白排泄量(UAE)及炎症因子白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的影响。方法将符合早期DN纳入标准的58例患者随机分为治疗组(32例)和对照组(26例),两组在基础治疗的基础上,对照组加服福辛普利,治疗组加服温肾健脾、祛毒活血中药,两组疗程均为1个月。观察治疗前后两组空腹血糖(FBG)、血脂、24hUAE、血清IL-6和TNF-α的变化。结果两组均能降低FBG、24hUAE及改善血脂;治疗组在降低24hUAE及改善各项血脂指标方面均明显优于对照组(P<0.05或P<0.01),且能降低患者血清IL-6、TNF-α水平(P<0.05或P<0.01)。结论温肾健脾、祛毒活血中药复方可改善血脂代谢紊乱、降低尿微量白蛋白,显著下调血清IL-6、TNF-α水平。
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2009年第2期175-177,共3页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 广东省佛山市卫生局课题(2005333)
  • 相关文献

参考文献8

  • 1World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication: report of a WHO Consultation. Part I. Diagnosis and classification of diabetes mellitus[ M]. Geneva, 1999.
  • 2Erik MC. Management of early nephropathy in diabetic patients [J ]. Annu RevMed, 1995, 46: 79-94.
  • 3郑莜萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.143-150.
  • 4李焱.炎症、胰岛素抵抗是2型糖尿病和动脉粥样硬化的共同基础[J].国外医学(内分泌学分册),2005,25(3):150-152. 被引量:48
  • 5刘军,陈影,刘芳,徐东丽,姚庆姑.2型糖尿病患者微、大血管病变与白细胞计数的关系[J].临床荟萃,2003,18(24):1400-1403. 被引量:14
  • 6吴国仲,吴永贵.糖尿病肾病发病炎症机制研究进展[J].国外医学(泌尿系统分册),2005,25(3):363-367. 被引量:46
  • 7Oyama I, Shimokata K, Niwa T, An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats[J]. Nephron, 2002, 92(3): 635-651.
  • 8Usui H, Shikata K, Matsuda M, et al. HMG - CoA reduetase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats[J]. Nephrol Dial Transplant, 2003; 18 (2) : 265 - 272.

二级参考文献28

  • 1钱浩,吴永贵,林辉,赵珉,周典,郝丽,张伯科.霉酚酸酯对糖尿病大鼠肾组织单核细胞趋化蛋白-1与细胞间黏附分子-1表达的影响[J].中华肾脏病杂志,2004,20(5):375-376. 被引量:9
  • 2[1]Woodman R J, Watts G F, Puddey I B,et al. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension[J]. Atherosclerosis,2002,163(1):175-181.
  • 3[2]Franco C, Paola M, Paolo P,et al. White blood cell count is positively correlated with albumin excretion rate in subjects with type 2 diabetes[J]. Diabetes Care,2002,25(12):2354-2355.
  • 4[3]WHO. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension[J]. J Hypertens,1999,17(2):151-183.
  • 5[4]Mueller C, Neumann F J, Perruchoud A P, et al. White blood cell count and long term mortality after non-ST elevation acute coronary syndrome treated with very early revascularisation [J]. Heart, 2003 ,89(4):389-392.
  • 6[5]Hung M J, Cherng W J. Comparison of white blood cell counts in acute myocardial infarction patients with significant versus insignificant coronary artery disease[J]. Am J Cardiol, 2003,91(11):1339-1442.
  • 7[6]Peter L, Paul M R, Attilio M. Inflammation and atherosclerosis[J]. Circulation,2002,105(9):1135-1143.
  • 8[7]Hasegawa T, Negishi T, Deguchi M. WBC count, atherosclerosis and coronary risk factors[J]. J Atheroscler Thromb, 2002,9(5):219-223.
  • 9[8]Aaron R F, Wayne D R, Eyal S, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke[J]. Circulation, 1999,100(7):736-742.
  • 10Guler S, Cakir B, Demirbas B, et al. Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res,2002,58:67 - 70.

共引文献382

同被引文献212

引证文献12

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部